Kelun scores sac-TMT win in first-line NSCLC population missing from Merck’s massive phase 3 program

The clinical blueprint for Merck & Co.’s prized TROP2-directed antibody-drug conjugate, sacituzumab tirumotecan (sac-TMT), could add a missing piece thanks to a landmark achieved by its partner | The clinical blueprint for Merck & Co.’s prized TROP2-directed antibody-drug conjugate, sac-TMT, could add a missing piece thanks to a landmark achieved by its partner, Kelun-Biotech.